Search

A 50-year-old man with cholangiocarcinoma exhibited lack of efficacy with gemcitabine and carboplatin and developed calciphylaxis during treatment with pemigatinib. His medical history included cirrhosis and thrombocytopenia, complicating his treatment. Despite various interventions and clinical trials, the man ultimately chose hospice care and passed away due to disease progression. The case highlights the challenges and complications that can arise in cancer treatment, emphasizing the importance of personalized care and monitoring for adverse reactions. [Extracted from the article]

A recent study from the Division of Rheumatology focused on vasculitis associated with VEXAS syndrome, a rare condition linked to a specific genetic mutation. The research found that a quarter of patients with VEXAS syndrome exhibited vasculitis, with small and medium vessel involvement being common. The study highlighted the importance of accurate diagnosis due to potential misinterpretation of symptoms. For more information, the full article can be accessed through the publisher, Oxford University Press. [Extracted from the article]

A retrospective cohort study examined 11 patients with penicillin-susceptible staphyylococcus aureus bacteraemia who experienced various toxicities while being treated with antibiotics such as benzylpenicillin, cloxacillin, cefazolin, amoxicillin/clavulanic-acid, vancomycin, or piperacillin/tazobactam. The toxicities included allergic reactions, liver function test abnormalities, rashes, pruritus, fever with leukopenia, angioedema, and hypersensitivity reactions. The patients were diagnosed with penicillin-susceptible staphylococcus aureus bacteraemia and experienced adverse reactions during treatment. [Extracted from the article]

A recent study from the Division of Dermatology in Washington, D.C., focused on a 13-year-old girl with tuberculosis who developed a full-body rash. Skin biopsies revealed leukocytoclastic vasculitis and tuberculid pathologies, highlighting the importance of early histopathology for accurate diagnosis. The research emphasizes the need to differentiate these rashes from other common diseases to ensure prompt treatment. This study has been peer-reviewed and provides valuable insights into the complexities of vasculitis in adolescents. [Extracted from the article]

A recent report from Mayo Clinic in Rochester, Minnesota, discusses the diagnostic utility of direct immunofluorescence (DIF) testing for cutaneous vasculitis. The scoping review aimed to evaluate the peer-reviewed literature on the use of DIF in vasculitis, with findings suggesting a sensitivity of 75% for DIF. The research highlights the importance of DIF testing not only for diagnostic confirmation but also for disease subtype classification and prediction of systemic associations in vasculitis. Future studies are recommended to compare the sensitivity of DIF to histopathology in vasculitis diagnosis. [Extracted from the article]

A 56-year-old man developed cutaneous leukocytoclastic vasculitis (CLV) while being treated with rifampicin for pulmonary tuberculosis. The onset of symptoms occurred 3 weeks after starting isoniazid, rifampicin, and levofloxacin for tuberculosis. After stopping the medications and starting prednisolone, the CLV resolved within 2 weeks. The man was found to have mono-resistance to rifampicin, and other medications were re-initiated without recurrence of symptoms. [Extracted from the article]

A man developed leukocytoclastic vasculitis while being treated with terbinafine and itraconazole for dermatophyte infections. Despite receiving immune-globulin and unspecified steroids, he did not respond to treatment and ultimately passed away due to the vasculitis. The vasculitis was believed to be a result of the medications he was taking. [Extracted from the article]

A 71-year-old woman developed immunoglobulin A (IgA) vasculitis while being treated with vedolizumab for ulcerative colitis (UC). Despite previous treatment with mesalazine and corticosteroids for over 11 years, she showed lack of efficacy. The woman presented with purpura on her limbs, which led to a diagnosis of IgA vasculitis secondary to vedolizumab therapy. Treatment with prednisolone resulted in the prompt disappearance of purpura, and her UC was well-controlled with continued vedolizumab therapy. [Extracted from the article]

A 75-year-old man developed leukocytoclastic vasculitis (LCV) while being treated with rituximab for low-grade orbital B-cell lymphoma. He experienced symptoms such as a maculopapular red rash, low-grade fever, myalgia, and arthralgia. Laboratory results showed abnormalities in various parameters. After ruling out other possible causes, the diagnosis of rituximab-induced LCV was confirmed. The man's rituximab therapy was discontinued, and he was started on methylprednisolone, leading to complete recovery. [Extracted from the article]

A 53-year-old man developed levamisole-induced leukocytoclastic vasculitis after using cocaine adulterated with levamisole. He presented with bilateral lower extremity pain and swelling, and a physical exam revealed a purpuric rash on his legs. Blood work showed elevated C-reactive protein levels, and a punch biopsy confirmed the diagnosis. The patient was treated with triamcinolone and showed improvement before being discharged from the hospital. This case highlights the potential for drug-drug interactions and adverse reactions associated with polysubstance drug abuse. [Extracted from the article]

Researchers at Tabriz University of Medical Sciences have published a case report on psoriatic arthritis, a chronic inflammatory condition associated with psoriasis that affects the joints. The report focuses on a 56-year-old male patient with a history of psoriasis and psoriatic arthritis who presented with new-onset skin lesions and neurological symptoms. The patient was diagnosed with vasculitis, an inflammation of blood vessels, which is rare in psoriatic arthritis cases. The case highlights the complex nature of autoimmune conditions and the need for further research to understand the underlying mechanisms and improve management strategies. [Extracted from the article]

A 24-year-old man developed Henoch-Schonlein purpura (HSP) after receiving the tozinameran (Pfizer-BioNTech COVID-19) vaccine. He experienced a rash, arthralgia, and abdominal pain, along with elevated white blood cell count and proteinuria. A biopsy confirmed leukocytoclastic vasculitis, consistent with HSP. Treatment with tofacitinib temporarily improved symptoms, but they relapsed. Prednisone was then prescribed, leading to resolution of symptoms. The patient's blood tests returned to normal, and he was tapered off prednisone over three months. [Extracted from the article]

In a retrospective study conducted between January 2018 and September 2023, 12 patients aged 60-94 years were observed to have experienced impaired renal function, thrombopenia with epistaxis, or lack of efficacy with dalbavancin, rifampicin, or cefditoren for various types of endocarditis. Complications of endocarditis included heart failure, abscesses, embolisms, osteomyelitis, renal failure, and other serious conditions. The patients had previously been treated with various medications before being switched to dalbavancin, rifampicin, or cefditoren. Unfortunately, 10 of the patients experienced clinical failure and ultimately died due to complications related to endocarditis or other infections. [Extracted from the article]

A case report from Nippon Medical School in Tokyo, Japan, describes a 73-year-old man with advanced lung squamous cell carcinoma who developed symptoms of IgA vasculitis after receiving carboplatin, nab-paclitaxel, and pembrolizumab treatment. The patient experienced purpuras, joint swelling, abdominal pain, diarrhea, acute kidney injury, increased proteinuria, hematuria, and elevated C-reactive protein levels. Skin biopsy confirmed the diagnosis of IgA vasculitis, and symptoms resolved after discontinuation of pembrolizumab and glucocorticoids. The researchers recommend regular monitoring and consideration of immune-related adverse events in patients receiving immune checkpoint inhibitors. [Extracted from the article]

A recent research study conducted by the University of Tunis El Manar in Tunisia investigated inflammatory markers associated with cutaneous leukocytoclastic vasculitis (CLV). The study aimed to compare these markers and determine their potential role in distinguishing between secondary leukocytoclastic vasculitis (SLV) and idiopathic leukocytoclastic vasculitis (ILV). The study included 77 patients with CLV, with 52 in the SLV group and 25 in the ILV group. The results showed significant differences in mean values of platelet-to-lymphocyte ratio (PLR), neutrophil-to-lymphocyte ratio (NLR), C-reactive protein (CRP)-to-albumin ratio (CAR), and fibrinogen-to-albumin ratio (FAR) between the two groups. The study concluded that elevated ratios of PLR, CAR, and FAR are associated with SLV, suggesting the need for further exploration of patients with elevated ratios. [Extracted from the article]

A 39-year-old man developed progressive disseminated histoplasmosis (PDH) while being treated for presumed Reiter's syndrome. He experienced recurring symptoms despite pharmacological treatment and eventually developed cutaneous lesions, leukocytoclastic vasculitis, and chronic interstitial nephritis. Over the course of several years, he was treated with various immunomodulatory drugs, but his condition continued to worsen. He eventually passed away due to PDH. The development of PDH was attributed to the immunosuppressive effects of the medications he was taking. [Extracted from the article]

A 50-year-old man developed IgA vasculitis while being treated with allopurinol for gout. He presented with a rash on his lower extremities and abdomen, along with diarrhea. Physical examination revealed purpura and pink papules on his skin. Laboratory tests showed elevated antistreptolysin O titre and C-reactive protein. A biopsy confirmed the diagnosis of IgA vasculitis, and it was also discovered that the man had asymptomatic COVID-19, which contributed to the vasculitis. He was successfully treated with prednisone and topical corticosteroids, and both the vasculitis and COVID-19 eventually resolved. [Extracted from the article]

A 66-year-old man developed immunoglobulin A vasculitis after receiving the AZD-1222 COVID-19 vaccine. He presented with widespread palpable purpura, vesicles on his extremities, and joint swelling and arthralgia. The man, who had underlying health conditions, was admitted to the hospital due to purpura progression and diabetic foot issues. A biopsy confirmed immunoglobulin A vasculitis caused by the vaccine, and he was treated with steroids, leading to improvement in his skin lesions. [Extracted from the article]

A case report from Nippon Medical School in Tokyo, Japan, discusses the development of IgA vasculitis in a 73-year-old man with advanced lung squamous cell carcinoma who was receiving carboplatin, nab-paclitaxel, and pembrolizumab treatment. The patient experienced symptoms such as purpura, joint swelling, abdominal pain, and diarrhea, along with acute kidney injury and elevated protein levels. Skin biopsy confirmed the diagnosis of IgA vasculitis, which was determined to be an immune-related adverse event induced by the treatment. The report emphasizes the importance of regular monitoring and considering the possibility of immune-related adverse events in patients receiving immune checkpoint inhibitors. [Extracted from the article]

The Malaysian National Pharmaceutical Regulatory Agency (NPRA) is warning healthcare professionals about the risk of cutaneous leucocytoclastic vasculitis after administering injectable azacytidine. Cutaneous vasculitis is inflammation of small or medium-sized blood vessels in the skin. The European Medicines Agency (EMA) has requested that product registration holders of azacitidine-containing injectable formulations update their package inserts with information about cutaneous vasculitis. The NPRA has received reports of adverse events related to azacitidine, but no cases of cutaneous vasculitis have been reported in Malaysia. Healthcare professionals should be aware of the potential risk and inform patients to seek medical attention if they experience unusual or worsening skin symptoms after receiving azacitidine. The NPRA has issued a directive for registration holders to update package inserts with this safety information. There is currently no evidence to update package inserts for oral azacitidine products, but the NPRA will continue to monitor the safety profiles of all azacitidine products. [Extracted from the article]

A 65-year-old woman with erythema elevatum diutinum (EED) experienced a lack of efficacy with multiple drugs, including ciclosporin, dapsone, methotrexate, and mycophenolate mofetil. Despite receiving these treatments, her skin lesions continued to progress. Surgical excision of the nodules was unsuccessful, and the lesions regrew at the surgical site. Further investigation revealed bone abnormalities within the skull, and the woman was ultimately treated with thalidomide and cyclophosphamide, which resulted in the resolution of her skin lesions. [Extracted from the article]

Three case reports were described in which women aged between 36-71 years developed eosinophilic granulomatosis with polyangiitis (EGPA) while being treated with various antiasthmatic medications. In one case, treatment failure was observed with mepolizumab and benralizumab, and EGPA was considered secondary to dupilumab. In another case, lack of efficacy was seen with omalizumab, mepolizumab, and tralokinumab, and EGPA was considered secondary to dupilumab. In the third case, EGPA was considered secondary to benralizumab. Corrective treatment was initiated in all cases. [Extracted from the article]

The article discusses research by Kan Katayama from the Department of Nephrology, reported in the August 19, 2024 issue of Internal Medicine, on renal medullary angiitis associated with cutaneous leukocytoclastic vasculitis. Topics include the presentation of renal medullary angiitis with neutrophil infiltration, diagnostic findings including negative immunofluorescence and no immune-dense deposits, and the treatment response to intravenous methylprednisolone and plasma exchange.

A 61-year-old woman experienced multiple toxicities while being treated with pembrolizumab for clear cell renal cell carcinoma. She developed myocarditis, acute motor and sensory axonal polyneuropathy, colitis, hypothyroidism, hepatitis, and purpura fulminans. The woman was admitted to the ICU with symptoms of haemodynamic instability, heart failure, and purpura fulminans. She was diagnosed with immune-induced myocarditis, polyneuropathy, colitis, hypothyroidism, hepatitis, and purpura fulminans. Treatment with pembrolizumab was discontinued, and the woman received methylprednisolone, immune-globulin, plasma exchanges, and surgery. After four months, her corticosteroids were gradually tapered down, and at a six-month follow-up, her skin lesions had completely healed. [Extracted from the article]

Two case reports describe patients who developed leukocytoclastic vasculitis (LCV) and injection site pain after receiving the AZD-1222 (Oxford/AstraZeneca) or tozinameran (Pfizer-BioNTech) COVID-19 vaccines. The first patient, a 59-year-old man, experienced rashes, swelling, and injection site pain after the AZD-1222 vaccine. He was diagnosed with LCV and treated with steroids, which resolved his skin lesions. The second patient, an 87-year-old woman, developed skin lesions and injection site pain after the tozinameran vaccine. She was also diagnosed with LCV and treated with prednisone and colchicine, resulting in significant improvement in her skin lesions. Both patients declined to receive the second dose of the vaccine. [Extracted from the article]

A 3-year-old boy with a history of skin rashes and a positive family history of autoimmune and renal disease was diagnosed with Henoch-Schönlein purpura (HSP). He was treated with prednisone, but the treatment was not effective as he continued to have persistent lesions. It was suggested that the lack of efficacy may have been due to a hypersensitivity reaction and vasculitis secondary to COVID-19. The boy's symptoms improved with colchicine treatment and the rash eventually healed within a few days. [Extracted from the article]

A report from Careggi University Hospital in Florence, Italy discusses the findings of research on vasculitis, a group of diseases characterized by inflammation and damage to the walls of pulmonary vessels. The research highlights the difficulty of diagnosing pulmonary vasculitis based on radiological features alone, as the symptoms can overlap with other conditions. The aim of the study is to provide a detailed description of the most common radiological features of lung involvement in pulmonary vasculitis to aid in prompt diagnosis, along with clinical history and laboratory tests. The research emphasizes the importance of a multidisciplinary approach to accurately diagnose and treat pulmonary vasculitis. [Extracted from the article]

A recent study conducted at the First Affiliated Hospital of Zhejiang Chinese Medical University in China has explored the development of drug-induced vasculitis, specifically focusing on propylthiouracil (PTU)-induced vasculitis. The researchers found that PTU, which is commonly used to treat Graves' disease, can lead to the development of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). The study highlights the importance of considering pregnancy preparation needs and avoiding drugs with reproductive toxicity and serious adverse events in patients with drug-induced vasculitis. The researchers recommend a multidisciplinary combination therapy approach involving low-dose glucocorticoids, immunosuppressants, and iodine radiotherapy to treat this condition. [Extracted from the article]

A male patient developed cryptococcoid vasculopathy while being treated with hydralazine for leukocytoclastic vasculitis. He experienced acute onset necrotic bullae and retiform purpura all over his body, and skin biopsy revealed dermal edema and a dense neutrophilic infiltrate. The patient was also diagnosed with lupus anticoagulant hypoprothrombinemia syndrome. Unfortunately, he passed away due to cryptococcoid vasculopathy. [Extracted from the article]

A 25-year-old woman developed IgA vasculitis (IgAV) and experienced vaccination failure after receiving the elasomeran vaccine for immunization against SARS-CoV-2 infection. The woman noticed skin rashes on her lower limbs and forearms three months after the second dose of elasomeran. Recurrent episodes of the rash occurred three times at intervals of approximately seven days. She also developed mild upper respiratory symptoms and was diagnosed with SARS-CoV-2 breakthrough infection. Later, she experienced severe epigastric pain, arthralgia, and a skin rash eruption. The woman was diagnosed with systemic IgAV of the skin, duodenum, and joints as an adverse reaction to elasomeran. She was treated with prednisolone and achieved symptom relief. She decided not to receive the third dose of elasomeran and did not experience any flare-ups of IgAV without prednisolone treatment for over six months. [Extracted from the article]

A recent study conducted at Qilu Hospital of Shandong University explores the relationship between vasculitis and thromboembolic disease. The study found that thromboembolic events often occur during periods of vasculitic disease, although the exact mechanism is still unclear. The researchers conducted a systematic review of literature to investigate the etiology, pathophysiology, and treatment methods for vasculitis. They discovered that certain systemic inflammatory diseases, like vasculitis, are associated with a higher risk of both venous and arterial thrombosis. The study suggests that immunosuppression may be effective in managing venous thrombosis in vasculitis patients, who also have an increased risk of developing ischemic disease. [Extracted from the article]

Researchers from Tunis El Manar University have conducted a case-based review on Sjogren's Syndrome, an autoimmune exocrinopathy. The study focuses on a 57-year-old female patient who presented with Guillain-Barre syndrome (GBS) followed by acute headaches and cortical blindness. The patient was diagnosed with primary Sjogren's syndrome (pSS) based on immunological disturbances and symptoms. The research emphasizes the importance of careful clinical assessment, radiological findings, and immunological markers in diagnosing and treating pSS. [Extracted from the article]

An 81-year-old man experienced acute kidney injury and leukocytoclastic vasculitis while being treated with apixaban and enoxaparin-sodium for atrial fibrillation. The man had a history of chronic kidney disease, atrial fibrillation, and chronic obstructive pulmonary disease. After starting apixaban, his renal function worsened, but improved when enoxaparin-sodium was initiated. However, after re-initiating apixaban, the man developed pulmonary consolidations, oedema, and haematuria. He was treated with methylprednisolone, underwent haemodialysis, and had a kidney biopsy that confirmed anticoagulant-related nephropathy. The man ultimately died from acute kidney injury, leukocytoclastic vasculitis, and multiple organ failure. The vasculitis and kidney injury were considered to be caused by apixaban and enoxaparin-sodium. [Extracted from the article]

A 78-year-old woman developed immunoglobulin A vasculitis while being treated with ciprofloxacin and metronidazole for acute diverticulitis. She presented with a skin rash on her feet that spread to her lower limbs and buttocks, along with symptoms of diarrhea, vomiting, and abdominal pain. Initial tests indicated leukocytoclastic vasculitis and immunoglobulin A vasculitis, and a skin biopsy confirmed the diagnosis. The woman was treated with methylprednisolone and made a full recovery after discontinuing the antibiotics. [Extracted from the article]

A 78-year-old woman developed immunoglobulin A vasculitis while being treated with ciprofloxacin and metronidazole for acute diverticulitis. She presented with a skin rash on her feet that spread to her lower limbs and buttocks, along with symptoms of diarrhea, vomiting, and abdominal pain. Initial tests indicated leukocytoclastic vasculitis and immunoglobulin A vasculitis, and a skin biopsy confirmed the diagnosis. The woman was treated with methylprednisolone and made a full recovery after discontinuing the antibiotics. [Extracted from the article]

A 41-year-old man developed antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis while being treated with propylthiouracil for Grave's disease. He presented with skin ulcers, fevers, and elevated inflammatory markers. The man also developed pancytopenia and was found to have positive ANA, MPO, and PR3 antibodies. Biopsy confirmed leukocytoclastic vasculitis, and he was later diagnosed with diffuse alveolar hemorrhage. The patient received treatment with steroids and hydroxychloroquine and was discharged after two weeks of hospitalization. [Extracted from the article]

A 52-year-old male developed leukocytoclastic vasculitis while being treated with cefazolin for a methicillin-resistant Staphylococcus aureus infection and abscess. The patient initially complained of pain in the left forearm, which was later found to have an intravenous blood clot and signs of thrombophlebitis and an abscess. After starting cefazolin and draining the abscess, the patient experienced oedema, palpable purpura, and ulcers in the lower legs. A skin biopsy confirmed leukocytoclastic vasculitis, and the patient was switched to clindamycin and treated with prednisolone. The skin lesions eventually resolved after 8 weeks. [Extracted from the article]

A 41-year-old man developed antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis while being treated with propylthiouracil for Grave's disease. He presented with skin ulcers, fevers, and elevated inflammatory markers. The man also developed pancytopenia and was found to have positive ANA, MPO, and PR3 antibodies. Biopsy confirmed leukocytoclastic vasculitis, and he was later diagnosed with diffuse alveolar hemorrhage. The patient received treatment with steroids and hydroxychloroquine and was discharged after two weeks of hospitalization. [Extracted from the article]

A 52-year-old male developed leukocytoclastic vasculitis while being treated with cefazolin for a methicillin-resistant Staphylococcus aureus infection and abscess. The patient initially complained of pain in the left forearm, which was later found to have an intravenous blood clot and signs of thrombophlebitis and an abscess. After starting cefazolin and draining the abscess, the patient experienced oedema, palpable purpura, and ulcers in the lower legs. A skin biopsy confirmed leukocytoclastic vasculitis, and the patient was switched to clindamycin and treated with prednisolone. The skin lesions eventually resolved after 8 weeks. [Extracted from the article]

A recent study conducted by researchers at the University of Naples in Italy explored the use of high-resolution brain vessel wall magnetic resonance imaging (VW-MRI) in diagnosing central nervous system (CNS) vasculitis. The study included 14 patients with confirmed CNS vasculitis, with diagnoses including primary CNS vasculitis (PCNSV) and secondary CNS vasculitis (SCNSV). The researchers found that intense, concentric vessel wall enhancement in VW-MRI was often present in patients with CNS vasculitis, particularly in the anterior circulation. Additionally, they observed a correlation between areas of vessel wall enhancement and diffusion-weighted imaging (DWI) changes. These findings suggest that VW-MRI could be a valuable tool in diagnosing CNS vasculitis, complementing other imaging techniques. [Extracted from the article]

A study conducted at Yerevan State University in Armenia focused on a rare case of phenobarbital-induced leukocytoclastic vasculitis (LCV). The study found that drug hypersensitivity reactions manifested as vasculitis are uncommon, and there is limited information about barbiturates as a cause. The researchers presented a case of a 53-year-old female who developed severe vasculitis after using medications containing phenobarbital and NSAIDs. Through diagnostic examinations and long-term observation, phenobarbital was identified as the most probable culprit drug. The study emphasizes the importance of awareness and proper recording of cases involving phenobarbital to manage and prevent drug hypersensitivity reactions manifested as vasculitis. [Extracted from the article]

A recent study conducted by researchers at the University of Oxford in the United Kingdom has shed light on a condition called cryofibrinogen-associated necrotising cutaneous vasculitis. Cryofibrinogen is an abnormal protein that can be found in the plasma of healthy individuals as well as those with autoimmune diseases, cancer, and infections. The study focused on a 76-year-old male patient who presented with necrotising ulcers in his lower limbs, along with high inflammatory markers and a history of large vessel vasculitis. The patient was treated with immunosuppressive therapy and showed significant improvement. The researchers concluded that more research is needed to optimize treatment protocols for patients with cryofibrinogen-associated systemic vasculitis. [Extracted from the article]

A report from the University of Belgrade discusses the case of a young male with severe diffuse toxic goitre who experienced hand and foot skin changes resembling PTU-induced vasculitis. The researchers emphasize the importance of clinicians being aware of the side effects of medications, particularly after their introduction and long-term use. The patient's skin changes were ultimately diagnosed as Hand, Foot, and Mouth disease (HFMD), which can resemble PTU-induced vasculitis. This case study highlights the need for careful evaluation and monitoring of unusual clinical scenarios related to drug use. [Extracted from the article]

A recent report from the Connective Tissue Diseases Research Center discusses the occurrence of vasculitis in patients with ankylosing spondylitis (AS). While vasculitis is uncommon in AS, patients with AS who exhibit symptoms such as skin petechiae, purpura, abdominal discomfort, malaise, elevated ESR, and reduced complement levels should be monitored for vasculitis. The report presents a case study of a 48-year-old male with AS who developed abdominal pain and skin lesions after stopping his medication. Clinical evaluations confirmed leukocytoclastic vasculitis (LCV) related to AS, ruling out other potential causes. [Extracted from the article]

A recent study conducted at Ruhr-University Bochum in Germany compared the clinical and laboratory data of adult patients with cutaneous IgA vasculitis (aIgA-SVV) and non-IgA vasculitis. The study found several differences between the two conditions, suggesting that they are not the same entity. Patients with non-IgA vasculitis had a higher platelet-to-lymphocyte ratio and lower serum C3 levels and mean corpuscular hemoglobin concentration compared to patients with aIgA-SVV. Proteinuria and hematuria were more common in patients with aIgA-SVV and were correlated with systemic immune-inflammation biomarkers. The study concluded that aIgA-SVV and non-IgA-SVV are similar conditions but not the same. [Extracted from the article]

A 77-year-old woman developed leukocytoclastic vasculitis after receiving a vaccination for influenza. She had a history of lymphoma and was undergoing immunosuppressant drug therapy with sirolimus and mycophenolate-mofetil. The woman experienced joint pain, diarrhea, and fever after the vaccination, and later developed painful erythematous nodules on her arms and legs. A biopsy confirmed the diagnosis of leukocytoclastic vasculitis, which was attributed to the combination of the influenza vaccine and the immunosuppressant drugs. Treatment with prednisone resulted in complete resolution of the condition. [Extracted from the article]

An 89-year-old woman developed cutaneous small vessel vasculitis and thrombocytopenia while being treated with amiodarone for atrial fibrillation. She had a medical history of hypertension, hypothyroidism, and paroxysmal atrial fibrillation. After being admitted to the hospital for dyspnea and atrial fibrillation with rapid ventricular rate, she received a bolus of amiodarone and subsequently developed thrombocytopenia and purpuric macules and patches on her fingertips, fingertip pads, palms, and left big toe. A punch biopsy confirmed a diagnosis of leukocytoclastic vasculitis. The woman's amiodarone treatment was discontinued and she fully recovered within two weeks. [Extracted from the article]

A recent report published by researchers at the Department of Internal Medicine and Clinical Immunology in Melun, France, discusses a rare manifestation of leukocytoclastic vasculitis called annular erythema. The report describes a case of a 36-year-old woman who presented with annular erythema, fever, joint arthralgia, and petechial purpura. A skin biopsy confirmed the diagnosis of immunoglobulin A vasculitis with annular leukocytoclastic vasculitis. The patient showed improvement with topical steroids. This research highlights the rare occurrence of this variant of vasculitis and provides valuable insights into its diagnosis and treatment. [Extracted from the article]

A recent study conducted by researchers from Lebanese University focused on histiocytic necrotizing lymphadenitis, specifically Kikuchi-Fujimoto disease (KFD). The study presented a rare case report of a 22-year-old female patient who experienced a flare-up of leukocytoclastic vasculitis, which was complicated by the appearance of a cervical lymph node with dysphagia, fever, and nausea. The patient was diagnosed with histiocytic necrotizing lymphadenitis and showed improvement with intravenous corticosteroids. The study emphasizes the importance of considering KFD in patients with autoimmune or inflammatory diseases who develop lymphadenopathies. [Extracted from the article]

A recent study conducted at a tertiary care hospital examined the histopathological features of cutaneous vasculitis and its clinical correlation. The study found that cutaneous vasculitis can present with various morphologies, including urticaria, purpura, ulcers, and infarcts. By analyzing vessel size, inflammatory response, and conducting immuno uorescence examination, a specific diagnosis can be made, leading to more effective therapy. The study also identified leukocytoclastic vasculitis as the most common type of vasculitis. The histopathological examination of skin biopsy plays a valuable role in confirming the clinical diagnosis of cutaneous vasculitis. [Extracted from the article]